SG11201702416YA - Methods for assessing risk of developing breast cancer - Google Patents

Methods for assessing risk of developing breast cancer

Info

Publication number
SG11201702416YA
SG11201702416YA SG11201702416YA SG11201702416YA SG11201702416YA SG 11201702416Y A SG11201702416Y A SG 11201702416YA SG 11201702416Y A SG11201702416Y A SG 11201702416YA SG 11201702416Y A SG11201702416Y A SG 11201702416YA SG 11201702416Y A SG11201702416Y A SG 11201702416YA
Authority
SG
Singapore
Prior art keywords
methods
breast cancer
developing breast
assessing risk
assessing
Prior art date
Application number
SG11201702416YA
Inventor
Richard Allman
Original Assignee
Genetic Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014903898A external-priority patent/AU2014903898A0/en
Application filed by Genetic Technologies Ltd filed Critical Genetic Technologies Ltd
Publication of SG11201702416YA publication Critical patent/SG11201702416YA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00Libraries per se, e.g. arrays, mixtures
    • C40B40/04Libraries containing only organic compounds
    • C40B40/06Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
SG11201702416YA 2014-09-30 2015-09-29 Methods for assessing risk of developing breast cancer SG11201702416YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2014903898A AU2014903898A0 (en) 2014-09-30 Methods for assessing the risk of developing breast cancer
PCT/AU2015/050583 WO2016049694A1 (en) 2014-09-30 2015-09-29 Methods for assessing risk of developing breast cancer

Publications (1)

Publication Number Publication Date
SG11201702416YA true SG11201702416YA (en) 2017-04-27

Family

ID=55629155

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201702416YA SG11201702416YA (en) 2014-09-30 2015-09-29 Methods for assessing risk of developing breast cancer

Country Status (11)

Country Link
US (2) US10920279B2 (en)
EP (1) EP3201360A4 (en)
JP (1) JP6820838B2 (en)
KR (1) KR102334702B1 (en)
CN (1) CN107002138B (en)
AU (2) AU2015327756B2 (en)
CA (1) CA2962691C (en)
IL (1) IL251376B (en)
MX (1) MX2017004127A (en)
SG (1) SG11201702416YA (en)
WO (1) WO2016049694A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006320559B2 (en) 2005-11-29 2012-01-19 Cambridge Enterprise Limited Markers for breast cancer
AU2010256343B2 (en) 2009-06-01 2014-01-30 Genetic Technologies Limited Methods for breast cancer risk assessment
JP6820838B2 (en) 2014-09-30 2021-01-27 ジェネティック テクノロジーズ リミテッド How to assess the risk of developing breast cancer
JP2020508643A (en) * 2017-01-24 2020-03-26 ジェネティック テクノロジーズ リミテッド Improved assessment of breast cancer risk
US20200354797A1 (en) * 2017-10-13 2020-11-12 Genetic Technologies Limited Methods of assessing risk of developing breast cancer
CN108060229A (en) * 2017-12-27 2018-05-22 沃森克里克(北京)生物科技有限公司 A kind of TERT genes rs10069690 sites SNP nucleic acid Mass Spectrometry detection methods
CN110628912A (en) * 2019-11-06 2019-12-31 上海韦翰斯生物医药科技有限公司 Primer and method for detecting polymorphism
KR102169699B1 (en) * 2019-12-27 2020-10-23 주식회사 클리노믹스 Customized DNA chip for genetic test and manufacturing method thereof)
CN112687330A (en) * 2020-12-29 2021-04-20 北京易奇科技有限公司 Risk prediction system for pathogenic variation of germ line carried by breast cancer patient
CN115762635A (en) * 2021-12-27 2023-03-07 河北北方学院附属第一医院 System for screening and risk prediction of liver cancer based on molecular marker and application

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54147035A (en) 1978-05-10 1979-11-16 Minolta Camera Co Ltd Tessar type photographic lens placed behind aperture
US4240608A (en) 1979-11-02 1980-12-23 Acf Industries, Incorporated Controlled float seat arrangement for expanding gate valves
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
EP0730663B1 (en) 1993-10-26 2003-09-24 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
PT912766E (en) 1996-06-04 2009-07-16 Univ Utah Res Found Monitoring hybridization during pcr
AU723400B2 (en) 1996-11-07 2000-08-24 Oklahoma Medical Research Foundation Diagnostic assay for breast cancer susceptibility
WO2000033161A2 (en) 1998-12-02 2000-06-08 Kiva Genetics, Inc. Methods to reduce variance in treatment studies using genotyping
US20020123095A1 (en) 1999-10-20 2002-09-05 Pe Corporation (Ny) Estrogen receptor alpha variants and methods of detection thereof
US20050084849A1 (en) 2000-07-25 2005-04-21 Moskowitz David W. Diagnostic polymorphisms for the ecnos promoter
US6812339B1 (en) 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
US20030092019A1 (en) 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
AU785425B2 (en) 2001-03-30 2007-05-17 Genetic Technologies Limited Methods of genomic analysis
WO2003012046A2 (en) 2001-07-27 2003-02-13 The Regents Of The University Of California Stk15 (stk6) gene polymorphism and methods of determining cancer risk
US7529685B2 (en) 2001-08-28 2009-05-05 Md Datacor, Inc. System, method, and apparatus for storing, retrieving, and integrating clinical, diagnostic, genomic, and therapeutic data
WO2003025141A2 (en) 2001-09-19 2003-03-27 Intergenetics Incorporated Genetic analysis for stratification of cancer risk
US20040023237A1 (en) 2001-11-26 2004-02-05 Perelegen Sciences Inc. Methods for genomic analysis
US6897025B2 (en) 2002-01-07 2005-05-24 Perlegen Sciences, Inc. Genetic analysis systems and methods
US7135286B2 (en) 2002-03-26 2006-11-14 Perlegen Sciences, Inc. Pharmaceutical and diagnostic business systems and methods
US7427480B2 (en) 2002-03-26 2008-09-23 Perlegen Sciences, Inc. Life sciences business systems and methods
US20040210400A1 (en) 2003-01-27 2004-10-21 Perlegen Sciences, Inc. Analysis methods for individual genotyping
US20040191783A1 (en) 2003-03-31 2004-09-30 Guy Leclercq Low density micro-array analysis in human breast cancer
US20050019787A1 (en) 2003-04-03 2005-01-27 Perlegen Sciences, Inc., A Delaware Corporation Apparatus and methods for analyzing and characterizing nucleic acid sequences
US7124033B2 (en) 2003-04-30 2006-10-17 Perlegen Sciences, Inc. Method for identifying matched groups
US20040229224A1 (en) 2003-05-13 2004-11-18 Perlegen Sciences, Inc. Allele-specific expression patterns
US20040241657A1 (en) 2003-05-28 2004-12-02 Perlegen Sciences, Inc. Liver related disease compositions and methods
US20050272043A1 (en) 2003-07-24 2005-12-08 Roth Richard B Methods for identifying risk of breast cancer and treatments thereof
AU2004271164A1 (en) 2003-09-04 2005-03-17 Intergenetics, Inc. Genetic analysis for stratification of breast cancer risk
US7127355B2 (en) 2004-03-05 2006-10-24 Perlegen Sciences, Inc. Methods for genetic analysis
US20090087854A1 (en) 2007-09-27 2009-04-02 Perlegen Sciences, Inc. Methods for genetic analysis
AU2006320559B2 (en) 2005-11-29 2012-01-19 Cambridge Enterprise Limited Markers for breast cancer
US20080009419A1 (en) 2006-06-23 2008-01-10 Intergenetics, Inc. Genetic models for stratification of cancer risk
US20080131887A1 (en) 2006-11-30 2008-06-05 Stephan Dietrich A Genetic Analysis Systems and Methods
US20110117545A1 (en) 2007-03-26 2011-05-19 Decode Genetics Ehf Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
EP2535425A1 (en) 2007-05-25 2012-12-19 Decode Genetics EHF. Variantes génétiques sur les chr 10q26 utilisées comme marqueurs dans l'évaluation, le diagnostic, le pronostic et le traitement d'un risque de cancer du sein
EP2176426A2 (en) 2007-07-11 2010-04-21 InterGenetics, Inc. Genetic models for stratification of cancer risk
WO2009097270A2 (en) * 2008-01-28 2009-08-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Method of determining breast cancer risk
WO2010017520A1 (en) 2008-08-08 2010-02-11 Navigenics, Inc. Methods and systems for personalized action plans
KR20110074527A (en) 2008-09-12 2011-06-30 네이비제닉스 인크. Methods and systems for incorporating multiple environmental and genetic risk factors
AU2010256343B2 (en) * 2009-06-01 2014-01-30 Genetic Technologies Limited Methods for breast cancer risk assessment
CN102575289A (en) * 2009-06-25 2012-07-11 耶鲁大学 Single nucleotide polymorphisms in brca1 and cancer risk
WO2013151413A1 (en) 2012-04-02 2013-10-10 Infovalley Life Science Sdn. Bhd. Methods and compositions for determining increased risk for breast cancer
JP6820838B2 (en) 2014-09-30 2021-01-27 ジェネティック テクノロジーズ リミテッド How to assess the risk of developing breast cancer
JP2020508643A (en) 2017-01-24 2020-03-26 ジェネティック テクノロジーズ リミテッド Improved assessment of breast cancer risk
US10609708B1 (en) 2017-06-27 2020-03-31 Sprint Spectrum L.P. Use of TDD special subframe for transmission of small quantity of data
US20200354797A1 (en) 2017-10-13 2020-11-12 Genetic Technologies Limited Methods of assessing risk of developing breast cancer

Also Published As

Publication number Publication date
KR102334702B1 (en) 2021-12-06
EP3201360A1 (en) 2017-08-09
MX2017004127A (en) 2017-10-24
US20180305764A1 (en) 2018-10-25
AU2018202299B9 (en) 2020-03-05
CA2962691A1 (en) 2016-04-07
WO2016049694A1 (en) 2016-04-07
US10920279B2 (en) 2021-02-16
CN107002138A (en) 2017-08-01
AU2018202299A1 (en) 2018-04-26
AU2015327756B2 (en) 2018-01-04
IL251376B (en) 2022-09-01
US10683549B2 (en) 2020-06-16
US20160222469A1 (en) 2016-08-04
IL251376A0 (en) 2017-05-29
JP2017529859A (en) 2017-10-12
AU2018202299B2 (en) 2019-10-24
CN107002138B (en) 2022-06-14
CA2962691C (en) 2023-05-23
KR20170063977A (en) 2017-06-08
EP3201360A4 (en) 2018-05-09
JP6820838B2 (en) 2021-01-27
AU2015327756A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
ZA201701753B (en) Biomarkers for assessing breast cancer
IL251376A0 (en) Methods for assessing risk of developing breast cancer
EP3524689C0 (en) Method for predicting the prognosis of breast cancer patient
SG10202011339RA (en) Microrna biomarker for the diagnosis of gastric cancer
GB2545361B (en) Methods of assessing colorectal cancer status
SG10201801562PA (en) Combination method for treatment of cancer
IL285077A (en) Compounds for treatment of cancer
GB201420859D0 (en) Tumour analysis
HK1253082A1 (en) Method of diagnosis of breast cancer
IL268235A (en) Improved methods for assessing risk of developing breast cancer
HK1224370A1 (en) Specific biomarker set for non-invasive diagnosis of liver cancer
IL273844A (en) Methods of assessing risk of developing breast cancer
SG10201913528PA (en) Methods of diagnosing cancer
DK3198034T3 (en) BIOMARKERS FOR CERVIX CANCERS
IL246558A0 (en) Novel methods for treating cancer
SG11201701076TA (en) Diagnosis of cancer
EP3534218C0 (en) Developing apparatus
PL3152576T3 (en) Use of tm9sf4 as a biomarker for tumor associated exosomes
GB201408297D0 (en) Treatment of cancer
IL246540A0 (en) Frizzled receptor antibodies for treatment of cancer
HK1249134A1 (en) Biomarkers for colorectal cancer related diseases
IL247270B (en) Method of detecting cancer
EP3189332A4 (en) Biomarkers for detection of breast cancer
EP3156502A4 (en) Evaluation method for evaluating the likelihood of breast cancer
GB201407837D0 (en) Methods of cancer therapy